Abstract

A mounting system for mounting a solar panel assembly to a base assembly includes a panel support bracket, a base bracket and a clamp configured to exert a compressive force to hold the panel support bracket and the base bracket together. The clamp comprises a V-shaped clamp body that includes a pair of legs that are spring-loaded to oppose an approximation of the legs by an external compressive force. The clamp includes a pair of receiver slots, with each of the pair of receiver slots located on a corresponding one of the pair of legs. The pair of receiver slots collectively provides a clearance to admit the panel support bracket and the base bracket when the legs are compressed together.

IPC Classes  ?

• H02S 30/10 - Frame structures
• F16B 5/06 - Joining sheets or plates to one another or to strips or bars parallel to them by means of clamps or clips
• H02S 20/23 - Supporting structures directly fixed to an immovable object specially adapted for buildings specially adapted for roof structures
• H02S 40/30 - Electrical components

Abstract

A system may include a plurality of compartments, wherein each compartment defines a respective internal volume. A system may include a plurality of odorous materials, wherein each compartment houses a respective odorous material within the respective internal volume. A system may include an integrated circuit (IC) chip comprising a processor and a memory, the memory having computer-executable instructions stored thereon that, when executed by the processor, cause the IC chip to monitor a respective state of each compartment.

IPC Classes  ?

• A61M 21/00 - Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis

Abstract

Benzyl derivative compounds having peroxisome proliferator-activated receptor α (PPARα) agonistic activity, kits and compositions containing such compounds, and methods of their use in enhancing PPARα activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

IPC Classes  ?

• C07F 9/38 - Phosphonic acids (R—P(:O)(OH)2); Thiophosphonic acids
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• C07F 9/30 - Phosphinic acids (R2=P(:O)OH); Thiophosphinic acids

Abstract

A method of screening a chemical substance as a drug candidate against High-grade serous ovarian carcinoma (HGSOC). Mice with xenograft tumors caused by a cell line comprising HGSOC cells which have been transduced with firefly luciferase gene (Luc), or by a cell line comprising cisplatin-resistant HGSOC cells which have been transduced with Luc are treated with the chemical substance to the mice for a predetermined treatment period. Effects that the chemical substance has on the mice are assessed after the predetermined treatment period. The cell lines may be, for example, OVCAR-8-Luc cells or cisplatin-resistant OVCAR-8-Luc cells.

IPC Classes  ?

• A61K 49/00 - Preparations for testing in vivo

Abstract

A method and composition for mitigating or reducing drug-induced ototoxicity or drug-induced hearing loss in a subject in need of such treatment, comprising: providing a drug delivery system which releases a therapeutic drug upon exposure to reactive oxygen species, wherein the drug delivery system comprises a thermoresponsive hydrogel containing therapeutic drug-loaded crosslinked hybrid nanoparticles and provides sustained therapeutic drug release. The crosslinked hybrid nanoparticles within which the therapeutic drug is loaded may comprise 10,12-Pentacosadiynoic acid (PCDA) and polypropylene sulfide-polyethylene glycol monomethyl ether (PPS-mPEG). The drug-induced ototoxicity or hearing loss may be caused by cisplatin or other platinum-based drugs.

IPC Classes  ?

• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 9/06 - Ointments; Bases therefor
• A61K 31/05 - Phenols
• A61K 47/10 - Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers

Abstract

An ICL has (1) an IC region having a real refractive index, the IC region configured to generate light based on interband transitions, (2) an outer cladding layer formed from a high-doped semiconductor material and having an outer cladding layer real refractive index which is lower than the IC region real refractive index, and (3) a metal contact to the outer cladding region. The ICL may further include an intermediate cladding layer positioned between the IC region and the outer cladding layer, and at least one SCL positioned between the IC region and the intermediate cladding layer. In one non-limiting embodiment the ICL comprises an outer cladding layer positioned on a p-type GaSb substrate, wherein the high-doped semiconductor material comprises n+-type InAsSb doped with silicon and the GaSb substrate is doped with beryllium or zinc. The ICL may instead comprise a semi-insulating substrate such as GaAs, Si, or InP.

IPC Classes  ?

• H01S 5/343 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser
• H01S 5/30 - Structure or shape of the active region; Materials used for the active region
• H01S 5/34 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers

Abstract

A method of treating a Doublecortin-like kinase 1 (DCLKl)-expressing cancer and inhibiting tumor metatastasis in a subject in need of such treatment by (1) providing a self-assembled micelle interfering ribonucleic acid (SAMiRNA) nanoparticle comprising a therapeutically effective amount of an RNA oligonucleotide having inhibitory activity against the expression or biological activity of DCLK1, (2) providing a therapeutically effective amount of a platinum-based anticancer drug, and (3) administering to the subject a combination treatment comprising the SAMiRNA nanoparticle and the platinum-based anticancer drug. The SAMiRNA nanoparticle and the platinum-based anticancer drug may be administered together or separately.

IPC Classes  ?

• A61K 31/712 - Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
• A61K 33/243 - Platinum; Compounds thereof

Abstract

An assay system and method for generating quantitative data for a subject and a method for treating prostate cancer in a subject by determining an expression level of a biomarker panel in a sample obtained from the subject, the biomarker panel including the genes CDC45, CENPI, CLSPN, ERCC6L, EXO1, NCAPG, BUB1B, CDK1, NUSAP1, RAD51, and RRM2 and optionally E2F7 and/or GSG2, wherein the expression level is obtained by measuring expression of the biomarker panel in the sample, and wherein the subject has a cancer, or is suspected of having a cancer. The cancer may be, for example, prostate cancer, brain cancer, lung cancer, breast cancer, bladder cancer, or ovarian cancer.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

A method of producing cyclohexane- 1 -carboxylate (CHC), including providing a growth medium comprising a yeast extract, and a crotonate salt; providing a culture of Syntrophus aciditrophicus (S. aciditrophicus); using the growth medium to initiate growth of the culture of S. aciditrophicus; after the S. aciditrophicus has initiated cell division, adding to the growth medium a benzoate salt, wherein after an incubation period, the CHC produced by the culturing of the S. aciditrophicus in the growth medium is purified. The incubation period may be continued until the amount of CHC in the growth medium has achieved a concentration of at least 1 g/l (7.8 mM).

IPC Classes  ?

• C12P 7/40 - Preparation of oxygen-containing organic compounds containing a carboxyl group

Abstract

The present disclosure is directed to methods of cancer treatment, for example of solid tumors, in which CGRP is inhibited, and optionally is administered in tandem with checkpoint inhibitor immunotherapy (e.g., inhibition of Programmed cell death protein 1 (PD-1), PD-1 ligand, and/or Cytotoxic T-lymphocyte-Associated protein 4 (CTLA-4)) to bolster anti-tumor immunity and lead to tumor rejection. In one non-limiting embodiment, for example, the cancer treated is breast cancer. In this manner, CGRP inhibitors that target neurochemicals secreted by sensory nerves and are used as migraine treatments can be repurposed in anti-tumor therapy.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Disclosed herein are compositions and methods for the treatment of comorbid post-traumatic stress disorder and alcohol use disorder.

IPC Classes  ?

• A61P 25/30 - Drugs for disorders of the nervous system for treating abuse or dependence
• A61P 25/24 - Antidepressants
• C07D 489/02 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
• C07D 489/06 - Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
• C07D 489/08 - Oxygen atom

Abstract

Variants of adrenomedullin (AM) and adrenomedullin 2/Intermedin (AM2/IMD) peptide are disclosed, wherein the variant peptides have high binding affinity and agonistic or antagonistic activity for at least one receptor complex CLR:RAMP3. The AM and AMD2 variants include chimeras which comprise portions of at least one of AM, AMD2, CORP, AMY and CT. Also disclosed are methods of using the variant peptides in therapeutic treatments.

IPC Classes  ?

• C07K 14/575 - Hormones
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

Provided herein are methods of using multi-task learning (MTL) neural network architecture for predicting many disease traits of an individual from their whole genome. The model used a shared latent genomic representation, and each trait was predicted from the shared representation via a task-specific hidden layer. The MTL models achieved higher predictive performance than single-task learning (STL) models for both cancer and non-cancer diseases.

IPC Classes  ?

• G16H 50/30 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for individual health risk assessment
• G06N 3/08 - Learning methods

Goods & Services

Clothing, namely, tops as clothing, shirts, t-shirts, long-sleeved shirts, athletic shirts, polo shirts, dress shirts, collared shirts, tank tops, sweatshirts, hooded sweatshirts, hoodies, pullovers, fleece pullovers, fleece tops, hats, baseball caps, bucket hats; headwear Entertainment services, namely, organizing and conducting collegiate athletic competitions; providing collegiate athletic and sporting events; providing information in the field of collegiate sports and collegiate athletic competitions; providing online videos featuring collegiate sports and collegiate athletic competitions, not downloadable; organizing community sporting and cultural events

Abstract

The invention provides a compound of formula (I): or a salt thereof, wherein A, B, C, R1, and R have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful for agonizing the activity of PPARα and for treating diseases modulated by PPARα, such as, for example, diabetic retinopathy, pain, and liver diseases including fibrosis, NASH and NAFLD. Certain compounds are also useful as both agonists of PPARα and inhibitors of STING.

IPC Classes  ?

• C07D 249/06 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles with aryl radicals directly attached to ring atoms
• C07D 277/28 - Radicals substituted by nitrogen atoms
• C07D 213/36 - Radicals substituted by singly-bound nitrogen atoms
• C07C 229/60 - Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
• A61P 27/02 - Ophthalmic agents

Abstract

A method for mapping phonon polaritons (PhPs) in a test nanostructured material for use in designing and fabricating a modified version of the test nanostructured material, and the modified nanostructured material thus fabricated, and devices comprising the modified nanostructured material.

IPC Classes  ?

• G01N 21/65 - Raman scattering
• B82Y 20/00 - Nanooptics, e.g. quantum optics or photonic crystals

Abstract

Provided herein are gold nanoparticles (AuNPs) and therapeutics agents co-encapsulated within non-ionic surfactant vehicles (AuNSVs) as well as therapeutic methods of using AuNSVs. Also provided herein are a millifluidic synthesis apparatus and process using ultrasonic mixing for producing AuNSVs encapsulating therapeutic or diagnostic agents, such as chemotherapeutics and/or mRNA.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 9/107 - Emulsions
• A61K 9/51 - Nanocapsules
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61P 35/00 - Antineoplastic agents

Abstract

Proton beams can deliver a highly targeted radiation dose to a narrow volume defined by their Bragg peaks. However, Bragg peak range uncertainties persist during dose delivery. Fortunately, pulsed proton beams generate protoacoustic emissions proportional to absorbed proton energy, thereby encoding dosimetry information in a detectable acoustic wave. The present embodiments provide methods and apparatuses to derive and model protoacoustic imaging with an ultrasound transducer, and examine the frequency characteristics of protoacoustic emissions, which are crucial parameters in imaging resolution.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy

Abstract

A cost-effective aerial detector device is configured to locate ferromagnetic objects in a survey area. The aerial detector device includes a UAV, a sensor housing suspended from the UAV, and the sensor module inside the sensor housing. The sensor module can be a smartphone that includes a magnetometer and a GPS unit. A method for locating a ferromagnetic target within the survey area includes the steps of launching the aerial detector device into the survey area, activating the magnetometer and GPS unit on the smartphone to obtain magnetic field measurements and location information, correlating the magnetic field measurements with corresponding location information to produced geolocated magnetic field data, identifying geolocated magnetic anomaly data from the geolocated magnetic field data, identifying one or more magnetic anomaly signatures for the ferromagnetic target, and determining the location of the ferromagnetic target from the location information associated with the target magnetic anomaly signature.

IPC Classes  ?

• G01V 3/08 - Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination or deviation operating with magnetic or electric fields produced or modified by objects or geological structures or by detecting devices
• G01V 3/16 - Electric or magnetic prospecting or detecting; Measuring magnetic field characteristics of the earth, e.g. declination or deviation specially adapted for use during transport, e.g. by a person, vehicle or boat specially adapted for use from aircraft
• G01V 3/38 - Processing data, e.g. for analysis, for interpretation or for correction

Abstract

A system and method for analyzing biological samples (e.g., epithelial tissues) is described herein, including a multispectral frequency-domain time-resolved fluorescence measuring system comprising a frequency-modulated continuous wave digital-pulse modulated diode laser (FM CW laser) and a light emission detector. The FM CW laser is configured for simultaneous multiwavelength excitation of a compound. The light emission detector is configured for simultaneous multispectral time-resolved fluorescence measurement of a fluorescence frequency response (FFR) of the compound. The compound may be in an epithelial tissue. The excitation is modulated at frequencies within a frequency range of less than 100 MHz. The FM CW laser may be configured to emit modulated excitation spanning a set of frequencies which comprises at least three different frequencies in a range between 1 to 99 MHz, the set comprising at least one frequency <50 MHz, and at least one frequency ≥50 MHz and <100 MHz.

IPC Classes  ?

• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 21/17 - Systems in which incident light is modified in accordance with the properties of the material investigated
• G01N 21/64 - Fluorescence; Phosphorescence

Abstract

A chimeric antigen receptor (CAR) comprising (1) an extracellular portion of human Fms-related tyrosine kinase 3 ligand (FLT3L) that binds to Fms-related tyrosine kinase 3 (FLT3), (2) a transmembrane domain, (3) a costimulatory signaling domain, and (4) an intracellular signaling domain. A nucleic acid sequence encoding the CAR. A vector and cell comprising the nucleic acid sequence encoding the CAR. A cell expressing the CAR. A composition of cells expressing the CAR. A method of administering the composition of cells expressing the CAR to a subject for stimulating in the subject an immune response against cells which express FLT3.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/02 - Antineoplastic agents specific for leukemia
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/725 - T-cell receptors
• C12N 5/0783 - T cells; NK cells; Progenitors of T or NK cells

Abstract

CAR cells and humanized antibodies targeting DCLK1 expressed on/in tumor cells or circulating cancer cells are described as a new method of cancer treatment. The antibodies and cells are safe and effective in patients and can be used to treat cancer expressing the DCLK1 proteins.

IPC Classes  ?

• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61K 35/17 - Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
• A61K 38/00 - Medicinal preparations containing peptides
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• C07K 14/725 - T-cell receptors
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing

Abstract

A radar system comprising a mechanically and electronically scalable and fully digital phased array radar (PAR) system, and methods or use, for example, for use in making weather observations. The system may be mobile and enables rapid (volume scans in seconds) and adaptive scanning. The PAR system is highly modular and most of the components are easily replaceable even while the PAR is operational.

IPC Classes  ?

• G01S 7/02 - RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES - Details of systems according to groups , , of systems according to group
• G01S 7/03 - RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES - Details of systems according to groups , , of systems according to group - Details of HF subsystems specially adapted therefor, e.g. common to transmitter and receiver
• G01S 7/40 - Means for monitoring or calibrating
• G01S 13/02 - Systems using reflection of radio waves, e.g. primary radar systems; Analogous systems
• G01S 13/42 - Simultaneous measurement of distance and other coordinates
• H01Q 3/26 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture
• H01Q 3/30 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase
• H01Q 21/00 - Antenna arrays or systems
• H01Q 21/06 - Arrays of individually energised antenna units similarly polarised and spaced apart
• G01S 13/95 - Radar or analogous systems, specially adapted for specific applications for meteorological use

Abstract

Compositions containing compositions of heparosan polymers linked to a particle, such as a metallic or polymeric or lipid-containing nanoparticle are described, for use in cell delivery applications.

IPC Classes  ?

• A61K 39/385 - Haptens or antigens, bound to carriers
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/61 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

The compound DMX-5804, IUPAC name 5-(4-(2-methoxyethoxy)phenyl)-7-phenyl-3,4a,7,7a-tetrahydro-4H-pyrrolo[2,3-d]pyrimidin-4-one, is a potent and selective inhibitor of mitogen-activated protein kinase kinase kinase kinase-4 (MAP4K4). The present disclosure describes a scalable and practical synthesis process for making DMX-5804. The process (1) doesn't rely on transition metals, (2) has reduced duration of reactions, (3) is streamlined with significantly improved yields using low cost raw materials, (4) includes no microwave-assisted reactions, (5) does not require column purification, and (6) generally results in crystalized products having over a 95% purity in each step. The present disclosure also describes DMX-5804 analogs and derivatives for use in inhibiting MAP4K4, and scalable and practical processes for making such DMX-5804 analogs.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07F 9/6561 - Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
• C07H 19/14 - Pyrrolo-pyrimidine radicals

Abstract

A method comprising: obtaining I/Q data associated with a received radar signal; performing background subtraction on the I/Q data to obtain a subtracted signal; applying an algorithm to the subtracted signal to obtain a filtered signal, wherein the algorithm is based on a MSE filter; performing time-gating on the filtered signal to obtain a time-gated signal; applying a FFT to convert the time-gated signal to a frequency-domain signal; and applying a calibration set to the frequency-domain signal to extract an RCS of an OUT; and a system for conducting the method.

IPC Classes  ?

• G01S 7/292 - Extracting wanted echo-signals
• G01S 7/32 - Shaping echo pulse signals; Deriving non-pulse signals from echo pulse signals
• G01S 7/41 - RADIO DIRECTION-FINDING; RADIO NAVIGATION; DETERMINING DISTANCE OR VELOCITY BY USE OF RADIO WAVES; LOCATING OR PRESENCE-DETECTING BY USE OF THE REFLECTION OR RERADIATION OF RADIO WAVES; ANALOGOUS ARRANGEMENTS USING OTHER WAVES - Details of systems according to groups , , of systems according to group using analysis of echo signal for target characterisation; Target signature; Target cross-section
• G01S 13/28 - Systems for measuring distance only using transmission of interrupted, pulse modulated waves wherein the transmitted pulses use a frequency- or phase-modulated carrier wave with time compression of received pulses

Abstract

A method of formulating a nanofluid for use in a geologic formation for determining an average pore size of the geologic formation by selecting a desired flow rate of the nanofluid under a predetermined applied pressure, using the calculated average pore size and desired flow rate to estimate a desired average viscosity of the nanofluid, and producing the nanofluid having the desired average viscosity by combining a quantity of nanoparticles with an aqueous medium. A nanofluid made by said process. A method of treating a geologic formation, such as a geothermal formation, by injecting said nanofluid into the geologic formation.

IPC Classes  ?

• C09K 8/84 - Compositions based on water or polar solvents
• B82Y 30/00 - Nanotechnology for materials or surface science, e.g. nanocomposites
• E21B 49/00 - Testing the nature of borehole walls; Formation testing; Methods or apparatus for obtaining samples of soil or well fluids, specially adapted to earth drilling or wells

Abstract

Alkynyl nicotinamide compounds that inhibit Rearranged During Transfection (RET) kinase mutants resistant to RET protein tyrosine kinase inhibitors (RET-TKIs); compositions comprising same; and their use for treating RET kinase-altered cancers.

IPC Classes  ?

• C07D 401/06 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or

Abstract

Methods of treating or mitigating, in a subject, traumatic brain injury (TBI), post-traumatic stress disorder (PTSD), and symptoms and conditions characteristic thereof, such as decreased cerebral blood flow (CBF), ischemia/hypoxia, and sensory, locomotor, generalized anxiety disorder (GAD), anxiety-like behaviors, and affective and cognitive dysfunction, by administering at least one Nociceptin Opioid Peptide (NOP) receptor partial agonist or antagonist to the subject. In at least certain non-limiting embodiments, subjects with TBI, PTSD, or both TBI and PTSD may be treated with at least one NOP receptor partial agonist or antagonist shortly after any type of TBI, thereby preventing or mitigating disrupted blood flow to the brain and the rapid and sustained impairments that would otherwise ensue.

IPC Classes  ?

• A61K 38/10 - Peptides having 12 to 20 amino acids
• A61K 31/444 - Non-condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/451 - Non-condensed piperidines, e.g. piperocaine having a carbocyclic ring directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61K 31/4706 - 4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
• A61K 31/485 - Morphinan derivatives, e.g. morphine, codeine
• A61K 31/5025 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

Methods of conducting perforation and hydraulic fracturing operations in a subterranean wellbore by analysis of rock samples collected during drilling of the borehole. The rock samples can be analyzed on-site or off-site to characterize the connected porosity of the rock of the frac stages of the wellbore, enabling identification of the frac stages with the highest connected Porosity. The perforation and fracking procedures of higher-quality (high connected porosity) stages of the wellbore are prioritized over the poorer-quality (low connected porosity) stages, thereby enhancing oil and/or gas recovery from the subterranean formation, and reducing costs by avoiding frac stages which will be low producers due to their low connected porosity values.

IPC Classes  ?

• E21B 43/26 - Methods for stimulating production by forming crevices or fractures
• E21B 49/00 - Testing the nature of borehole walls; Formation testing; Methods or apparatus for obtaining samples of soil or well fluids, specially adapted to earth drilling or wells
• G01N 15/08 - Investigating permeability, pore volume, or surface area of porous materials

Abstract

A variable temperature IR spectroscopy sample system includes a button sample holder and temperature control support assembly. The button sample holder may include a mesh sample retainer attached within a recess of a sample plate. A thermocouple can be used to determine the temperature of the mesh sample retainer. The temperature control support assembly is configured to support the button sample holder within the infrared spectrophotometer while controlling and adjusting the temperature of the sample contained within the button sample holder. The temperature control support assembly includes a thermoelectric module, generally comprising one or more thermoelectric chips (TECs), that is configured to selectively adjust the temperature of the button sample holder. The temperature control support assembly can also include a liquid coolant system to remove heat generated by the thermoelectric module and to maintain the temperature control support assembly at a relatively constant or ambient temperature.

IPC Classes  ?

• G01N 21/03 - Cuvette constructions
• G01N 21/35 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light

Abstract

The present disclosure provides a compound having the structure: The present disclosure provides a compound having the structure:

IPC Classes  ?

• A61K 31/404 - Indoles, e.g. pindolol
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N); Sulfinylamines (—N=SO); Sulfonylamines (—N=SO2)
• A61K 31/343 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/423 - Oxazoles condensed with carbocyclic rings
• A61P 27/02 - Ophthalmic agents
• C07C 317/32 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• C07D 209/08 - Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
• C07D 263/56 - Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
• C07D 305/06 - Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring atoms
• C07D 307/79 - Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 309/06 - Radicals substituted by oxygen atoms
• C07D 333/54 - Benzo [b] thiophenes; Hydrogenated benzo [b] thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 405/06 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
• C07D 495/04 - Ortho-condensed systems
• C12N 9/99 - Enzyme inactivation by chemical treatment

Abstract

A method comprises: obtaining an endoscope; obtaining a needle; inserting the endoscope into the needle to obtain a system; inserting the system into an animal body; obtaining an image of a tissue or a space in the animal body using the endoscope and OCT; performing identification of the tissue or the space based on an OCT system; estimating a distance from the needle to the tissue or the space based on the identification and the OCT system; and performing a procedure with the needle and based on the identification and the distance.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes ; Identification of persons
• A61B 17/34 - Trocars; Puncturing needles
• G16H 20/40 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture

Abstract

A dental composition comprising nitrogen-doped TiO2 nanoparticles, and a curable resin material, wherein the curable resin material comprises a polymer precursor component, and wherein the nitrogen-doped TiO2 NPs further comprise at least additional one dopant selected from the group consisting of Ag (silver), F (fluorine), P (phosphorus), and PO4 (phosphate). A method of using the dental composition in a dental application. The dental composition may be antibacterial in the absence of visible light or UV light.

IPC Classes  ?

• B01J 27/24 - Nitrogen compounds
• A61K 6/30 - Compositions for temporarily or permanently fixing teeth or palates, e.g. primers for dental adhesives
• A61K 6/62 - Photochemical radical initiators
• B01J 23/75 - Cobalt
• B01J 31/06 - Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing polymers
• B01J 31/38 - Catalysts comprising hydrides, coordination complexes or organic compounds containing in addition, inorganic metal compounds not provided for in groups of titanium, zirconium or hafnium
• B01J 35/39 - Photocatalytic properties
• B01J 35/45 - Nanoparticles
• B01J 37/02 - Impregnation, coating or precipitation

Abstract

An improved system and method for analyzing highly complex biological samples such as cell lysates and other mixtures which contain proteins. The disclosed system and method incorporates a thermal protein depletion step prior to subzero temperature long gradient UPLC-HDX-MS (ultra-performance liquid chromatography hydrogen deuterium exchange coupled with mass spectrometry) to substantially reduce protein content and complexity of the mixture so that analysis of particular proteins can be enhanced. In particular, the system and method is used to facilitate high-throughput analysis of protein-ligand interactions, for example for the identification of ligand targets and characterization of protein-ligand interactions such as identification of binding sites in cell lysates and other complex biological mixtures.

IPC Classes  ?

• G01N 30/72 - Mass spectrometers
• G01N 33/58 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
• G01N 30/04 - Preparation or injection of sample to be analysed

Goods & Services

Alcoholic beverages, namely, bourbon whiskey and distilled spirits

Goods & Services

Alcoholic beverages, namely, vodka and distilled spirits

Abstract

A cancer treatment method for treating a subject in need of such therapy, the method comprising administering a therapeutically-effective amount of a heteroarotinoid compound and a Poly (ADP -ribose) polymerase (PARP) inhibitor, wherein the therapeutically-effective amount yields a synergistic effect compared to an effect of the heteroarotinoid alone and an effect of the PARP inhibitor alone. A drug combination and kit comprising a heteroarotinoid, and a PARP inhibitor, wherein the drug combination has a synergistic effect against cancer cells compared to an effect of the heteroarotinoid alone and an effect of the PARP inhibitor alone. Non-limiting examples of heteroarotinoids include flexible heteroarotinoids such as SHetA2, SHetA3, SHetA4, SHetC2, SHetD3, SHetD4, SHetDS, SHetSO, SHet65, SHetlOO, OHet72, NHetl7, NHet86, or NHet90. Non-limiting examples of PARP inhibitors include Olaparib, Niraparib, Rucaparib, Talazoparib, Veliparib, Pamiparib, CEP 9722, E7016, Stenopanb, ABT-767, INO-lOOl, MP-124, Amelpanb, PJ34, and NMS-P118.

IPC Classes  ?

• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/502 - Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
• A61P 35/00 - Antineoplastic agents

Abstract

The disclosure describes a well which extends into a subterranean formation, such as a geothermal formation. The well comprises a wellbore having a portion having a first non-circular cross section, and a casing having a non-circular cross section. The casing is installed within the portion of the wellbore having a non-circular cross section. The well may be an injection well or an extraction well or both. One or more of the injection and extraction wells may be used as a system for heating a fluid and extracting the fluid as a heated fluid. The heated fluid may be used, for example, as an energy source to generate electricity.

IPC Classes  ?

• E21B 7/00 - Special methods or apparatus for drilling
• F03G 4/00 - Devices for producing mechanical power from geothermal energy
• F24T 10/13 - Geothermal collectors with circulation of working fluids through underground channels, the working fluids not coming into direct contact with the ground using tube assemblies suitable for insertion into boreholes in the ground, e.g. geothermal probes
• F24T 50/00 - Geothermal systems

Abstract

Peptide compounds, and compositions containing the peptide compounds, and methods for using the peptide compounds to treat infections, wounds, enhance acceptance of grafts such as skin grafts and organ grafts, and enhance the sensitivity of a bacterial pathogen to an antibiotic to which the bacterial pathogen has developed resistance.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61K 38/17 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

Compounds and methods for treating insulin resistance, obesity, Type 2 diabetes, Nonalcoholic fatty liver disease (NAFLD), and peroxisome proliferator-activated receptor gamma (PPARy) serine 273 phosphorylation in subjects in need of such therapy.

IPC Classes  ?

• C07D 209/18 - Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 3/04 - Anorexiants; Antiobesity agents
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method of treating a cholestasis liver condition in a subject by administering to the subject a first compound and a second compound, wherein the first compound is a fibroblast growth factor 19 (FGF19) analogue, and/or a bile acid-activated farnesoid x receptor (FXR) agonist, and the second compound is an apical sodium-dependent bile acid transporter (ASBT) inhibitor.

IPC Classes  ?

• A61K 38/18 - Growth factors; Growth regulators
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Abstract

A method comprising: obtaining I/Q data associated with a received radar signal; performing background subtraction on the I/Q data to obtain a subtracted signal; applying an algorithm to the subtracted signal to obtain a filtered signal, wherein the algorithm is based on a MSE filter; performing time-gating on the filtered signal to obtain a time-gated signal; applying a FFT to convert the time-gated signal to a frequency-domain signal; and applying a calibration set to the frequency-domain signal to extract an RCS of an OUT; and a system for conducting the method.

IPC Classes  ?

• G01S 13/00 - Systems using the reflection or reradiation of radio waves, e.g. radar systems; Analogous systems using reflection or reradiation of waves whose nature or wavelength is irrelevant or unspecified
• G01S 13/08 - Systems for measuring distance only

Abstract

In one aspect, the present disclosure provides compounds such as those with one or more quaternary ammonium ions joined by one or more aromatic rings. These compounds may have a formula: In one aspect, the present disclosure provides compounds such as those with one or more quaternary ammonium ions joined by one or more aromatic rings. These compounds may have a formula: In one aspect, the present disclosure provides compounds such as those with one or more quaternary ammonium ions joined by one or more aromatic rings. These compounds may have a formula: These compounds may be used in the treatment of a microbial infection such as a bacterial infection including infections of drug resistant strains of bacteria.

IPC Classes  ?

• C07C 255/51 - Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton to carbon atoms of non-condensed six-membered aromatic rings containing at least two cyano groups bound to the carbon skeleton
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• C07C 317/40 - Y being a hydrogen or a carbon atom
• C07D 249/04 - 1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
• C07D 295/155 - Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 495/04 - Ortho-condensed systems

Abstract

A Self-Explaining Decision Architecture (SEDA) for machine learning-based decision-making systems capable of generating intuitive explanations for its decisions in real time. SEDA makes use of a feature extraction subsystem and a sequence interpretation subsystem to identify patterns in data followed by a decision generation subsystem that determines appropriate actions based on those patterns. Internal state information from each of these subsystems is used to generate explanations of the system's decisions. Using this information to create explanations provides insight as to the data elements the system focused on when making decisions as well as the reasoning that was used. In at least one embodiment the system uses deep learning components including a combined convolutional neural network and long short-term memory network with attention mechanisms.

IPC Classes  ?

• G06N 20/00 - Machine learning
• G06N 3/00 - Computing arrangements based on biological models
• G06N 5/04 - Inference or reasoning models

Abstract

Compositions of anionic and cationic peptides which co-assemble under suitable conditions to form peptide nanostructures, methods of assembling the peptide nanostructures, and methods of use of the peptide nanostructures in hydrogels and as vaccines and vaccine adjuvants. The peptide nanostructures demonstrate stability once self-assembled and are biocompatible and have therapeutic functionality, particularly when equipped with additional functional features such as ligands, fluorophores, antigens, drugs, or other bioactive compounds.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants

Goods & Services

All-digital polarimetric, terrestrial, phased array radar configured for the prediction of the formation of severe weather Research in the field of digital polarimetric, terrestrial, phased array radar systems useful adapted for the prediction of severe weather formation

Goods & Services

Research in the field of digital polarimetric, terrestrial, phased array radar systems useful adapted for the prediction of severe weather formation

Goods & Services

All-digital polarimetric, terrestrial, phased array radar configured for the prediction of the formation of severe weather

Goods & Services

Medical monitoring devices for detecting the presence of carbon monoxide, alcohol, hydrogen sulfide, and other health-related biomarkers in exhalations Providing a smartphone and internet-based data visualization platform for medical professionals and patients featuring medical information obtained from remote locations via electronic patient monitoring devices, where the internet-based data visualization platform can be accessed in real-time by medical professionals for purposes of monitoring and diagnosing medical conditions, including in support of efforts to monitor smoking, drinking, and other substance abuse disorders

Abstract

A method of extracting viable bacterial cells from a soil sample by mixing a dispersant-surfactant solution with a soil sample to form a soil slurry, adding the soil slurry to a centrifuge tube containing a density gradient medium, centrifuging the centrifuge tube to form a solvent layer above the density gradient medium, wherein the solvent layer comprises viable bacterial cells, extracting the solvent layer containing the viable bacterial cells, combining the extracted solvent layer with a PBS solution to form a PBS-cell mixture, filtering the PBS-cell mixture to form a cell filtrate, depositing the cell filtrate into a second centrifuge tube containing a quantity of the density gradient medium, centrifuging the second centrifuge tube to form a second solvent layer comprising the viable bacterial cells, and extracting the second solvent layer from the second centrifuge medium to form a second cell filtrate comprising the viable bacterial cells.

IPC Classes  ?

• G01N 1/34 - Purifying; Cleaning
• G01N 1/10 - Devices for withdrawing samples in the liquid or fluent state

Abstract

The present invention provides vaccine compositions for preventing and/or treating cytomegalovirus (CMV) infection and methods of making and using the same.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61K 39/12 - Viral antigens
• C07K 14/74 - Major histocompatibility complex (MHC)

Abstract

Multispecific constructs, e.g., bispecific constructs, which comprise an anti-B cell binding arm that specifically binds to a B-cell-specific cell surface marker such as CD20, CD19, CD21, CD24, or CD38, and a second binding arm that specifically binds to CD68 protein, and optionally at least one additional binding arm, wherein the multispecific constructs bind specifically to naïve B cells which express transcription factor ARID3a. Methods of using the multispecific constructs to treat autoimmune disorders and/or diseases including but not limited to Systemic lupus erythematosus (SLE), and SLE flare-ups.

IPC Classes  ?

• C07K 16/46 - Hybrid immunoglobulins
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 37/00 - Drugs for immunological or allergic disorders
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
• G01N 33/53 - Immunoassay; Biospecific binding assay; Materials therefor
• C12N 5/10 - Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells

Abstract

Benzyl derivative compounds having peroxisome proliferator-activated receptor a (PPARa) agonistic activity, kits and compositions containing such compounds, and methods of their use in enhancing PPARa activity for treating diseases and/or conditions involving inflammation and/or angiogenesis, particularly ocular diseases and/or conditions such as but not limited to retinal inflammation, retinal neovascularization, retinal vascular leakage, retinopathy of prematurity, diabetic retinopathy, age-related macular degeneration, and diabetic macular edema.

IPC Classes  ?

• A61K 31/662 - Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
• C07C 15/04 - Benzene
• C07F 9/06 - Phosphorus compounds without P—C bonds
• C07F 9/38 - Phosphonic acids (R—P(:O)(OH)2); Thiophosphonic acids

Abstract

Systems, comprising: an aqueous medium, the aqueous medium having an amount of DNA disposed therein, the aqueous medium having one or more RNA polymerases disposed therein; and a non-aqueous medium. Methods, the methods comprising operating a system according to the present disclosure, so as to give rise to an RNA product disposed in the non-aqueous medium. Methods, comprising: with an RNA polymerase in an aqueous medium, effecting synthesis of an RNA product from template DNA, and selectively transferring the RNA product to a non-aqueous medium.

IPC Classes  ?

• C12P 19/34 - Polynucleotides, e.g. nucleic acids, oligoribonucleotides
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)

Abstract

A method is for detecting and localizing a wireless camera in an environment suspected to contain the wireless camera. The method comprises: instructing a user to perform a predetermined motion in the environment, wherein the predetermined motion is detectable within a detection range of a motion sensor of the wireless camera; scanning for and collecting a wireless traffic flow in the environment via a sniffing device; analyzing the wireless traffic flow to identify an OUI; comparing the OUI to an existing public OUI database to determine if the wireless traffic flow is generated by the wireless camera; when the wireless traffic flow is determined to have been generated by the wireless camera, concluding that the wireless camera is present in the environment; calculating a path distance of the predetermined motion when the wireless camera has been determined to be present in the environment; using a model to determine if the user performing the predetermined motion was in the detection range; and when the user is determined to have been in the detection range, determining a specific location of the wireless camera in the environment based on the path distance of the predetermined motion.

IPC Classes  ?

• G06T 7/70 - Determining position or orientation of objects or cameras
• G06F 3/01 - Input arrangements or combined input and output arrangements for interaction between user and computer
• H04L 9/40 - Network security protocols

Abstract

nn nn n ) are disclosed, wherein at least one sulfur moiety is linked to at least one hydroxyl of the repeat structure. Also disclosed are methods of producing and using these polymers.

IPC Classes  ?

• C08B 37/00 - Preparation of polysaccharides not provided for in groups ; Derivatives thereof
• A61K 31/727 - Heparin; Heparan

Abstract

An aerosol containment device is designed for use in containing aerosols discharged during a dental procedure. In some embodiments, the aerosol containment device includes a vacuum source, a vacuum hose connected to the vacuum source, a manifold connected to the vacuum hose, and a clear plastic shield connected to the manifold. The manifold includes a front inlet, a rear discharge connected to the vacuum hose, and a plenum extending between the front inlet and the rear discharge. In some embodiments, the manifold includes a plurality of entry vanes adjacent to the front inlet and a plurality of interior foils connected to the entry vanes. In other embodiments, the manifold includes a plurality of entry vanes adjacent to the front inlet and a plurality of interior vanes connected to the entry vanes. In other embodiments, the manifold does not include entry vanes, interior vanes, or interior foils.

IPC Classes  ?

• A61G 10/00 - Treatment rooms for medical purposes
• A61G 15/10 - Parts, details or accessories

Abstract

A clamp for connecting a module-level power electronics (MLPE) device to a photovoltaic module frame may include an apex joint and two leg assemblies each extending downward from the apex joint. Each of the two leg assemblies may include an upper leg, a lower leg, a front receiver formed by a space between the upper and lower legs, and a rear receiver opposite the front receiver. Each leg assembly may further include locking tabs to abut against a vertical surface of the frame. An external force may be applied to the two leg assemblies to transition the legs between a compressed configuration and an engaged configuration.

IPC Classes  ?

• H02S 30/10 - Frame structures
• H01R 4/48 - Clamped connections; Spring connections using a spring, clip or other resilient member
• F24S 25/634 - Clamps; Clips
• H02S 40/30 - Electrical components

Abstract

Systems and methods for treating misophonia include utilizing machine learning within a deep learning processor to allow a user to listen to ambient sounds from their environment without hearing trigger sounds. The method includes the steps of recording ambient sounds with one or more microphones, digitizing the recorded ambient sounds into digital signals, creating spectrographic data for the digital signals, comparing the spectrographic data against a signature library that comprises preprogrammed spectrographic data for the unwanted trigger sounds, identifying the spectrographic data that corresponds to the unwanted trigger sounds, removing the unwanted trigger sounds from the spectrographic data to provide filtered spectrographic data, converting the filtered spectrographic data into a filtered digital signal, converting the filtered digital signal into a filtered audio signal that does not include the unwanted trigger sounds, and playing the filtered audio signal to the user through the one or more speakers on the headset.

IPC Classes  ?

• H04R 1/10 - Earpieces; Attachments therefor

Abstract

Disclosed herein are quaternary ammonium cyanine dyes. The dyes exhibit different absorption/emission profiles at different pH levels. The compounds can be used to detect Lewis acidic species, including metal ions and protons, for instance as pH probes. The compounds can be used as agents for biological assays, including diagnostics like optical, fluorescent, and optoacoustic imaging, especially in the detection of cancerous and other unhealthy cells.

IPC Classes  ?

• A61K 31/4045 - Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
• A61K 31/395 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
• A61K 31/44 - Non-condensed pyridines; Hydrogenated derivatives thereof
• A61K 31/407 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine
• A61K 31/33 - Heterocyclic compounds

Abstract

Methods of forming hollow nanoparticles, methods of making templates for use in forming hollow nanoparticles, templates made by such methods, and hollow nanoparticles formed by such methods and templates.

IPC Classes  ?

• B01J 13/20 - After-treatment of capsule walls, e.g. hardening
• B01J 13/10 - Complex coacervation, i.e. interaction of oppositely charged particles

Abstract

An X-band dual-polarized slotted waveguide antenna (SWGA) array unit cell comprises a partial H-plane waveguide with a metal vane; and a conventional waveguide in a side-by-side arrangement with the partial H-plane waveguide. A spacing between elements of the X-band dual-polarized SWGA array unit cell in an azimuth plane is in a range of about 0.6 λo to about 0.5 λo. The X-band dual-polarized SWGA array unit cell has a one-dimensional (1D) electronic-scanning range of at least 84° (±42°) in the azimuth plane perpendicular to a waveguide axis. The X-band dual-polarized SWGA array unit cell has a cross-polarization isolation of about −60 decibels (dB) or less.

IPC Classes  ?

• H01Q 21/00 - Antenna arrays or systems
• H01Q 21/24 - Combinations of antenna units polarised in different directions for transmitting or receiving circularly and elliptically polarised waves or waves linearly polarised in any direction
• H01Q 3/36 - Arrangements for changing or varying the orientation or the shape of the directional pattern of the waves radiated from an antenna or antenna system varying the distribution of energy across a radiating aperture varying the phase by electrical means with variable phase-shifters

Abstract

Hydroxybenzamide derivative compounds having β-cell protective activity against ER stress, and methods of their use in treating diabetes and other conditions and diseases associated with ER stress. In one non-limiting embodiment, the derivative is 3-hydroxy-N-(4-(trifluoromethyl)benzyl)benzamide.

IPC Classes  ?

• C07D 233/88 - Nitrogen atoms, e.g. allantoin
• C07D 233/64 - Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
• C07C 235/46 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 235/34 - Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
• C07C 275/34 - Derivatives of urea, i.e. compounds containing any of the groups the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by singly-bound oxygen atoms having nitrogen atoms of urea groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes

Abstract

Drug combinations of a heteroarotinoid (e.g., SHetA2, SHetA3, SHetA4, SHetC2, SHetD3, SHetD4, SHetD5, SHet50, SHet65, SHet100, OHet72, NHet17, NHet86, or NHet90), and an Azabicyclooctan-3-one derivative (e.g., PRIMA-1 or PRIMAMET) and/or a CDK4/6 inhibitor (e.g., Palbociclib, Abemaciclib, Ribociclib, Narazaciclib (ON123300), Dalpiciclib, Dinaciclib, Milciclib, Seliciclib), which are effective as anti-cancer treatments, and kits and methods of use of such drug combinations.

IPC Classes  ?

• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/439 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
• A61P 35/00 - Antineoplastic agents

Abstract

Analogs and derivatives of omecamtiv mecarbil, including an 18F-labeled analog, and methods of synthesis thereof. Cardiac myosin targeting vectors comprising a lipid anchoring/solubilizing moiety conjugated to a head made of omecamtiv mecarbil or the OM analog or derivative. Liposomes comprising a cardiac-treating cargo molecule and the cardiac myosin targeting vector, and methods of treating a cardiac condition or disease in a subject by administering the liposomes to the subject.

IPC Classes  ?

• C07D 401/12 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

An interband cascade (IC) optoelectronic device constructed to have a plurality of IC stages, wherein each of the IC stages comprises: a hole injector; an electron injector; an active region coupled to the hole injector and the electron injector and comprising a first layer, wherein the first layer comprises a first material, and wherein the first material comprises InAsP or AlInAsP; a conduction band running through the hole injector, the electron injector, and the active region; and a valence band running through the hole injector, the electron injector, and the active region. In certain embodiments, the IC optoelectronic device may be a laser (ICL), a light-emitting diode (LED), a superluminescent light-emitting diode (SLED), a photodector, or a photovoltaic device.

IPC Classes  ?

• H01L 33/30 - Materials of the light emitting region containing only elements of group III and group V of the periodic system
• H01L 33/06 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by the semiconductor bodies with a quantum effect structure or superlattice, e.g. tunnel junction within the light emitting region, e.g. quantum confinement structure or tunnel barrier
• H01L 31/0304 - Inorganic materials including, apart from doping materials or other impurities, only AIIIBV compounds
• H01L 31/0352 - SEMICONDUCTOR DEVICES NOT COVERED BY CLASS - Details thereof characterised by their semiconductor bodies characterised by their shape or by the shapes, relative sizes or disposition of the semiconductor regions

Abstract

An artificial intelligence enabled advanced treatment management system (AI-ATMS) is configured to improve interactions and outcomes from a multidisciplinary patient care team. The AI-ATMS includes advanced integration with an artificial intelligence system with access to federated databases. The AI-ATMS is configured for the real-time engagement with the patient- treatment team in a manner that provides the patient-treatment team with context-related data elements, while also permitting the patient-treatment team with the ability to train the AI-ATMS during the engagement. The AI-ATMS may be for treating a cancer or other medical condition.

IPC Classes  ?

• G16H 80/00 - ICT specially adapted for facilitating communication between medical practitioners or patients, e.g. for collaborative diagnosis, therapy or health monitoring
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G06N 5/045 - Explanation of inference; Explainable artificial intelligence [XAI]; Interpretable artificial intelligence
• G06N 20/00 - Machine learning
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients

Abstract

Interfering nucleic acids and methods of their use in treat prostate cancers, such as aggressive prostate cancers. The nucleic acids may be, for example, short interfering RNA (siRNA), short hairpin RNA (shRNA), antisense RNA, DNA, antisense DNA, Chimeric Antisense DNA/RNA, and microRNA (miRNA) oligonucleotides. The oligonucleotide has a seed sequence that is complementary to a sequence of either a gene or an mRNA encoding an androgen receptor (AR) coregulator or a fragment thereof having AR coregulator activity. The nucleic acid compound may have a non-natural modification in the oligonucleotide, and/or an organic moiety conjugated to the oligonucleotide. The oligonucleotide has inhibitory activity against the expression or biological activity of the AR coregulator.

IPC Classes  ?

• C12N 15/113 - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides
• A61P 5/28 - Antiandrogens
• C07K 14/705 - Receptors; Cell surface antigens; Cell surface determinants
• A61P 35/00 - Antineoplastic agents

Abstract

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 39/00 - General protective or antinoxious agents
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Abstract

A novel shape memory polymer (SMP)-based device for surgical treatment of an intracorporeal defect (e.g., a void or anomaly) such as an intracranial aneurysm or fistula. In at least one non-limiting embodiment, the SMP device is a 3D-printed SMP material sized to specifically fit and thus occlude an intracranial aneurysm (ICA). The SMP device may be delivered to the intracorporeal defect via a catheter having a heating mechanism wherein the SMP device is raised above its glass transition temperature as it is deployed, causing the SMP device to return to its permanent shape after it is deployed into the intracorporeal defect. SMP device delivery systems that include the SMP devices, as well as methods of making and using the devices and systems, are also disclosed.

IPC Classes  ?

• A61B 17/12 - Surgical instruments, devices or methods, e.g. tourniquets for ligaturing or otherwise compressing tubular parts of the body, e.g. blood vessels or umbilical cord
• A61L 31/02 - Inorganic materials
• A61L 31/14 - Materials characterised by their function or physical properties

Abstract

The present invention includes a method of predicting and/or treating a recurrence of MS treating a patient with multiple sclerosis, the method comprising: obtaining a hematopoietic cell sample from a patient suspected of having a recurrence of multiple sclerosis (MS), wherein the patient was in relapse for MS; determining the number of CD19+, CD24+, CD38+ transitional B cells in the hematopoietic cell sample, and a level of expression of neurofilament light (NFL) and interleukin-1β (IL-1β), which is predictive of a recurrence of MS; and treating the MS patient with recurrence until there is an increase in CD19+, CD24+, CD38+ transitional B cells and/or a decrease in a level of expression of NFL and interleukin-1β (IL-1β) when compared to an untreated MS control sample, an unresponsive MS control sample, or an MS patient with long-term stable disease sample.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
• G01N 33/569 - Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses

Abstract

A dental composition, and methods of use thereof, for causing tooth whitening and/or tooth mineralization without causing tooth hypersentivity. The dental composition contains a gel-forming thickening agent and nitrogen-doped titanium dioxide nanoparticles. The nitrogen- doped titanium dioxide nanoparticles may be co-doped with fluorine and/or silver. The dental composition may contain a bleaching agent.

IPC Classes  ?

• A61Q 11/00 - Preparations for care of the teeth, of the oral cavity or of dentures, e.g. dentifrices or toothpastes; Mouth rinses
• A61K 6/72 - Fillers comprising nitrogen-containing compounds
• A61K 6/816 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising ceramics comprising titanium oxide
• C01G 23/047 - Titanium dioxide

Abstract

An ICL comprises: a plurality of IC stages, wherein each of the IC stages comprises: a hole injector; an electron injector; an active region coupled to the hole injector and the electron injector and comprising a first layer, wherein the first layer comprises a first material, and wherein the first material comprises InAsP or AlInAsP; a conduction band running through the hole injector, the electron injector, and the active region; and a valence band running through the hole injector, the electron injector, and the active region.

IPC Classes  ?

• H01S 5/34 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers
• H01S 5/343 - Structure or shape of the active region; Materials used for the active region comprising quantum well or superlattice structures, e.g. single quantum well [SQW] lasers, multiple quantum well [MQW] lasers or graded index separate confinement heterostructure [GRINSCH] lasers in AIIIBV compounds, e.g. AlGaAs-laser

Abstract

A mounting system for mounting a solar panel assembly to a base assembly includes a panel support bracket, a base bracket and a clamp configured to exert a compressive force to hold the panel support bracket and the base bracket together. The clamp comprises a V-shaped clamp body that includes a pair of legs that are spring-loaded to oppose an approximation of the legs by an external compressive force. The clamp includes a pair of receiver slots, with each of the pair of receiver slots located on a corresponding one of the pair of legs. The pair of receiver slots collectively provides a clearance to admit the panel support bracket and the base bracket when the legs are compressed together.

IPC Classes  ?

• H02S 30/10 - Frame structures
• F16B 5/06 - Joining sheets or plates to one another or to strips or bars parallel to them by means of clamps or clips
• H02S 20/23 - Supporting structures directly fixed to an immovable object specially adapted for buildings specially adapted for roof structures
• H02S 40/30 - Electrical components

Abstract

The present disclosure describes a system comprising a gain-scheduling control strategy which improves its nonlinear control performance. A control-oriented model, which does not require numerous physical parameters and extensive test data, has been developed to address the nonlinearity of the fan system. Based on theoretical model and experimental verifications, the issue of an aggressive response with a conventional fixed-gain controller is caused by the fact that the system gain is proportional to the ratio of the duct static pressure to the fan speed. To address the issue, a scheduling function of the measurable duct static pressure and fan speed is included in the conventional fixed-gain controller to compensate for the fan system gain variation. The gain-scheduling control strategy approximately maintains the identical control performance under all operation conditions. The gain-scheduling control strategy can be readily implemented on a processor without intensive computation and additional measurements.

IPC Classes  ?

• F24F 11/77 - Control systems characterised by their outputs; Constructional details thereof for controlling the supply of treated air, e.g. its pressure for controlling air flow rate or air velocity by controlling the speed of ventilators
• F24F 11/63 - Electronic processing
• F24F 11/46 - Improving electric energy efficiency or saving
• G05B 19/042 - Programme control other than numerical control, i.e. in sequence controllers or logic controllers using digital processors

Abstract

The present disclosure is directed to methods of cancer treatment, for example of solid tumors, in which CORP is inhibited, and optionally is administered in tandem with checkpoint inhibitor immunotherapy (e.g., inhibition of Programmed cell death protein 1 (PD-1), PD-1 ligand, and/or Cytotoxic T-lymphocyte- Associated protein 4 (CTLA-4)) to bolster anti-tumor immunity and lead to tumor rejection. In one non-limiting embodiment, for example, the cancer treated is breast cancer. In this manner, CORP inhibitors that target neurochemicals secreted by sensory nerves and are used as migraine treatments can be repurposed in anti-tumor therapy.

IPC Classes  ?

• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans
• A61K 39/395 - Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• A61P 35/00 - Antineoplastic agents
• C07K 16/28 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Abstract

Compositions and methods of treating hyperglycemia in a subject having such a condition are disclosed. An inhibitor compound which causes activity of Cullin RING E3 ligases (CRL) to be reduced is administered to the subject, wherein blood glucose concentration is decreased. In at least certain embodiments insulin secretion and insulin sensitization in the subject are increased. Inhibition of CRL activity, e.g., by decreasing cullin neddylation by inhibiting NEDD8-activating enzyme (NAE), or decreasing cullin activity, e.g., by inhibiting expression of cullins, is shown herein to delay IRS protein turnover in liver cells and muscle cells, thereby increasing cellular response to insulin and decreasing blood glucose. Thus, inhibition of CRLs, for example by inhibiting neddylation, is an effective method to treat hyperglycemia and insulin resistance, and to increase insulin secretion in patients with hyperglycemia, for example due to type-2 diabetes.

IPC Classes  ?

• A61K 31/7064 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
• A61K 31/519 - Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A method for making a radiopharmaceutical cold kit without lyophilization, comprising (1) providing a labeling ligand, a reducing agent, and a bulking agent, and at least one of an antioxidant and an exchange ligand, wherein each of said labeling ligand, reducing agent, bulking agent, antioxidant and exchange ligand is provided in a dry form; and (2) combining and mixing the labeling ligand, the reducing agent, the bulking agent, and at least one of the antioxidant and the exchange ligand to produce a dry powder mixture, wherein the wherein the dry powder mixture is produced without the use of a lyophilization step. The radiopharmaceutical cold kit comprising the dry powder mixture may be stored, or combined with a radionuclide such as Technetium-99m (99mTc).

IPC Classes  ?

• A61K 51/12 - Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes
• A61K 51/04 - Organic compounds

Abstract

A test apparatus and method for applying one or more tensile loads to a sample and for testing attributes of the sample exposed to the one or more tensile loads. The test apparatus includes a housing that has a plurality of interconnected sides that contain the sample during testing and provide a rigid support structure to offset the tensile loads applied to the sample. The test apparatus includes one or more force application assemblies that are each configured to apply a particular tensile load on the sample. Each of the force application assemblies includes an anchor for securing the sample to the housing, a connector attached to an opposite side of the sample from the corresponding anchor, and a tension rod assembly configured to apply the tensile load between the housing and the sample.

IPC Classes  ?

• G01N 3/08 - Investigating strength properties of solid materials by application of mechanical stress by applying steady tensile or compressive forces
• G01N 3/06 - Special adaptations of indicating or recording means
• G01N 33/38 - Concrete; Lime; Mortar; Gypsum; Bricks; Ceramics; Glass

Abstract

Compositions, kits, and methods of use of branched poly(ethylenimine) (BPEI) compounds, including polyethylene glycol (PEG)-branched poly(ethylenimine) conjugates (PEG-BPEI) for treatment of diseases, bacterial infections, bacterial biofilms, and conditions associated with inflammation, including wounds.

IPC Classes  ?

• A61K 31/785 - Polymers containing nitrogen
• A61K 47/60 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• A61P 31/04 - Antibacterial agents
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7052 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

Disclosed herein are systems, methods, devices, and media for the risk for diseases and conditions in a patient. Deep neural networks enable the automated analysis of a patient’s SNP profile to generate predictions of a patient’s risk for developing a disease or condition.

IPC Classes  ?

• G06N 3/04 - Architecture, e.g. interconnection topology
• G06N 3/02 - Neural networks

Abstract

The present invention includes a method and kit of determining that a patient negative for anti- Ro autoantibodies has Sjögren’s syndrome (SS) without performing a lip biopsy comprising: obtaining a liquid biological sample from the patient suspected of having SS; determining that the patient is negative for anti-Ro autoantibodies; and detecting autoantibodies to 1, 2, 3, 4, 5, 6, 7, 8, or 9 proteins selected from: CCDC155, DDB1, MUM1L1, NFU1, RPS29, SOX5, TCP10, ZNF655, or RPAP3, which indicate(s) that the patient has SS. Also, a lack of certain autoantibodies such as KCNAB1, KCNAB2, or as listed in Table 1, Table 2, or Table 3, and FIGS. 11 or 16 in Ro neg cases may be used to detect SS.

IPC Classes  ?

• G01N 33/564 - Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease

Abstract

Microparticulate drug compositions comprising nanocrystals of poorly soluble drugs combined with a carrier are disclosed. Also disclosed are pharmaceutical compositions that include the microparticulate drug compositions. Further disclosed are methods of preparing and using the microparticulate drug compositions/pharmaceutical compositions.

IPC Classes  ?

• A61K 9/16 - Agglomerates; Granulates; Microbeadlets
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes

Abstract

The present invention includes composition and methods for preventing, reducing or eliminating progression of osteoarthritis in a human patient comprising identifying a human patient in need of treatment for progression of osteoarthritis associated with an altered intestinal flora; and providing the human patient with a composition comprising at least one of: Actinobacteria actinomycetales; Actinobacteria coriobacteriia; Coriobacteriia coriobacteriales; Bacilli bacillales; Bacilli lactobacillales Clostridia clostridiales; one or more agents that increase an amount of the Actinobacteria actinomycetales; Actinobacteria coriobacteriia; Coriobacteriia coriobacteriales; Bacilli bacillales; Bacilli lactobacillales Clostridia clostridiales in the intestinal flora of the human patient; or one or more agents that decrease the amount of Bacteroidetes and Firmicutes clostridia bacteria in an intestinal flora of the human patient bacteria in an intestinal flora of the human patient to prevent, reduce or eliminate progression of osteoarthritis.

IPC Classes  ?

• A61K 35/741 - Probiotics
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
• A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
• G16H 10/40 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for data related to laboratory analysis, e.g. patient specimen analysis
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• C12Q 1/04 - Determining presence or kind of microorganism; Use of selective media for testing antibiotics or bacteriocides; Compositions containing a chemical indicator therefor
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

Modified exosomes are disclosed that include an exosome and a targeting modality that extends outwardly from a surface membrane of the exosome. Also disclosed are methods of producing and using the modified exosomes.

IPC Classes  ?

• C07K 16/22 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors
• A61P 35/00 - Antineoplastic agents
• C07K 17/04 - Peptides being immobilised on, or in, an organic carrier entrapped within the carrier, e.g. gel, hollow fibre

Abstract

Compositions and methods for treating and/or diagnosing a subject having COVID-19. The treatment composition includes an inhibitor of at least one of doublecortin-like kinase 1 (DCLK1, including DCLK1 isoforms 1-4), and doublecortin-like kinase 2 (DCLK2, including DCLK2 isoforms 1-3). The treatment composition may optionally include an inhibitor of SI 00 calcium binding protein A9 (S100A9), calprotectin (S100A8/S100A9 complex), S100A4, Granulocyte-macrophage colony-stimulating factor (GM-CSF), Vascular endothelial growth factor (VEGF), Interleukin-6 (IL-6), or combinations thereof. The subject may also have a chronic liver disease, disorder, or condition. A method of determining if a patient having COVID-19 should be administered a treatment protocol for severe or critical COVID-19.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• C12N 9/12 - Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
• C07K 16/40 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against enzymes
• A61P 31/14 - Antivirals for RNA viruses

Abstract

A method of manufacturing a lead salt thin film on a substrate by seeding a substrate with a lead salt solution (e.g., PbSe, PbS, or PbTe) to form a seeded substrate comprising lead salt seed crystals, and growing the lead salt thin film upon the substrate by exposing the seeded substrate to a chemical bath comprising the lead salt solution at a predetermined growth temperature. A lead salt thin film manufactured by the process. A photonic crystal microchip comprising the lead salt thin film. A gas sensing device comprising a diode laser, a mid-infrared photodetector, and the photonic crystal microchip. A method of detecting a hydrocarbon gas, comprising exposing a gas sample to the gas sensing device, and determining the content of hydrocarbon gases in the gas sample.

IPC Classes  ?

• H01L 31/032 - Inorganic materials including, apart from doping materials or other impurities, only compounds not provided for in groups
• H01L 31/0304 - Inorganic materials including, apart from doping materials or other impurities, only AIIIBV compounds
• H01L 31/028 - Inorganic materials including, apart from doping material or other impurities, only elements of Group IV of the Periodic System

Abstract

Tracking patient compliance with treatment protocols is an important aspect of delivering high quality healthcare. A system for tracking compliance with protocols that include the periodic consumption of oral medication includes a mobile computing device and a pill tracking dispenser. The mobile computing device includes an application program configured to record the periodic consumption of oral medication by the patient. The pill tracking dispenser can be connected to the mobile computing device through a wireless network. The pill tracking dispenser is configured to report to the mobile computing device the number of times the oral medication is consumed by the patient.

IPC Classes  ?

• A61J 7/02 - Pill counting devices
• A61J 7/00 - Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
• A61J 7/04 - Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers
• G16H 20/13 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered from dispensers

Abstract

A method comprises: performing training and testing of an initial machine model to create a final machine model, wherein the training and testing use focal loss; performing detection of dead detector elements in a digital detector of a second digital radiographic (DR) imaging system using the final machine model; and determining whether to replace or keep the digital detector based on the detection. An apparatus comprises: a memory; and a processor coupled to the memory and configured to: perform training and testing of an initial machine model to create a final machine model, wherein the training and testing use focal loss; perform detection of dead detector elements in a digital detector of a second digital radiographic (DR) imaging system using the final machine model; and determine whether to replace or keep the digital detector based on the detection.

IPC Classes  ?

• A61B 6/00 - Apparatus for radiation diagnosis, e.g. combined with radiation therapy equipment
• G06V 10/776 - Validation; Performance evaluation
• G06V 10/774 - Generating sets of training patterns; Bootstrap methods, e.g. bagging or boosting
• G06V 20/70 - Labelling scene content, e.g. deriving syntactic or semantic representations

Abstract

The present disclosure is concerned with taccalonolide analogs and conjugated taccalonolide analogs useful as cellular probes and in the treatment of, for example, hyperproliferative disorders such as cardiovascular diseases and cancer. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.

IPC Classes  ?

• C07J 53/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton has been modified by condensation with carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms
• C07J 71/00 - Steroids in which the cyclopenta[a]hydrophenanthrene skeleton is condensed with a heterocyclic ring
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61P 35/00 - Antineoplastic agents

Abstract

An ICIP comprises: a number Ns of IC stages, wherein Ns is configured to achieve a fundamental limit of the detectivity Dpeak* the ICIP within a range, and wherein each of the IC stages comprises: a hole barrier; an absorber coupled to the hole barrier and comprising a thickness d, wherein d is configured to achieve Dpeak* within the range; and an electron barrier coupled to the absorber. A method of manufacturing an ICIP comprises: determining a number Ns of IC stages of the ICIP, wherein Ns is configured to achieve a peak detectivity Dpeak* of the ICIP within a range; determining a thickness d of an absorber, wherein d is configured to achieve Dpeak* within the range; obtaining a substrate; forming an electron barrier on the substrate, the absorber having d on the electron barrier, and a hole barrier on the absorber; and repeating the forming Ns times.

IPC Classes  ?

• H01L 31/111 - Devices sensitive to infrared, visible or ultraviolet radiation characterised by at least three potential barriers, e.g. photothyristor
• H01L 31/18 - Processes or apparatus specially adapted for the manufacture or treatment of these devices or of parts thereof

Abstract

The present invention describes novel tumor-specific phosphorylated peptides, nucleic acids encoding those peptides, and antibodies generated against said peptides. The genes, peptides, and antibodies described herein may be used as diagnostic indicators of the presence of breast cancer and/or used in therapeutics to treat breast cancer.

IPC Classes  ?

• C07K 7/08 - Linear peptides containing only normal peptide links having 12 to 20 amino acids
• C07K 14/47 - Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from humans from vertebrates from mammals
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• C07K 7/06 - Linear peptides containing only normal peptide links having 5 to 11 amino acids
• C07K 16/18 - Immunoglobulins, e.g. monoclonal or polyclonal antibodies against material from animals or humans

Abstract

Provided are methods useful for preventing and mitigating radiation injury, including acute radiation syndrome, comprising administering to a subject a therapeutically effective amount of a compound represented by formula I or a pharmaceutically acceptable salt thereof, wherein Z is —O— or —N(H)—.

IPC Classes  ?

• A61K 31/454 - Non-condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
• A61P 39/00 - General protective or antinoxious agents
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles

Abstract

Compositions containing compositions of heparosan polymers linked to a particle, such as a metallic or polymeric or lipid-containing nanoparticle are described, for use in cell delivery applications.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Compositions containing compositions of heparosan polymers linked to a particle, such as a metallic or polymeric or lipid-containing nanoparticle are described, for use in cell delivery applications.

IPC Classes  ?

• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 47/69 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit

Abstract

Proton beams can deliver a highly targeted radiation dose to a narrow volume defined by their Bragg peaks. However, Bragg peak range uncertainties persist during dose delivery. Fortunately, pulsed proton beams generate protoacoustic emissions proportional to absorbed proton energy, thereby encoding dosimetry information in a detectable acoustic wave. The present embodiments provide methods and apparatuses to derive and model protoacoustic imaging with an ultrasound transducer, and examine the frequency characteristics of protoacoustic emissions, which are crucial parameters in imaging resolution.

IPC Classes  ?

• A61N 5/10 - X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
• A61N 7/02 - Localised ultrasound hyperthermia
• A61B 8/00 - Diagnosis using ultrasonic, sonic or infrasonic waves

Abstract

The present disclosure provides a compound having the structure : Formula (I) or Formula (II).

IPC Classes  ?

• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N); Sulfinylamines (—N=SO); Sulfonylamines (—N=SO2)
• C07C 317/22 - Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
• A61P 27/02 - Ophthalmic agents